Research and Development

Watch an animated overview of the Eye90 microspheres® Administration Procedure and learn about the potential for our technology to improve outcomes for patients with liver tumors

Scientific Excellence

 

ABK-affiliated researchers regularly present and publish new data and findings at top international conferences and in peer-reviewed journals.

Visit our Scientific Research Portal to learn more about the promise of Eye90 microspheres Precision Dosimetry™ for patients with liver cancers.

Listen to Mike Mangano, president and CEO discussing the strides ABK Biomedical is taking to advance the treatment of liver cancer

Latest News

February 12th 2024

Interventional Oncology related Journals, Conferences and Societies Recognize ABK’s Breakthrough Technology Development

Go to Recent Awards»»

January 2024

ISO Certification

Go to Recent History»»

December 5th 2023

ABK Biomedical Announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)

Go to the Press Release»»

October 24th 2023

ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma 

Go to the Press Release»»

May 30th 2023

ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma

Go to the Press Release»»

December 6th 2022

ABK Biomedical Raises USD 30M in Series C Funding

Go to the Press Release»»

September 12th 2022

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

Go to the Press Release»»

September 12th 2022

ABK Biomedical announces the appointment of Dr. Aravind Arepally as Chief Medical Officer effective, September 12th 2022

Meet Our New CMO»»

Company News & Press Releases

ABK Biomedical Announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)

Halifax, Nova Scotia. December 5th, 2023. ABK Biomedical, Inc, an innovative, clinical-stage medical device company dedicated to the research…

Read the Press Release»»

ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma

Halifax, Nova Scotia. May 30th, 2023. ABK Biomedical an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies

Read the Press Release»»

ABK Biomedical Raises USD 30M in Series C Financing

Halifax, Nova Scotia. December 6th 2022. ABK Biomedical an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies

Read the Press Release»»

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

Halifax, Nova Scotia. September 12th 2022. ABK Biomedical, an innovative medical device company dedicated to the research…

Read the Press Release»»

Our Products

Eye90 microspheres logo

Eye90 microspheres®

A novel technology for Y90 radioembolization made with a proprietary, imageable glass composition for in-procedure visualization.

Bland embolization with easi-vue embolic microspheres

Easi-Vue™ embolic microspheres

Imageable bland embolization product allowing direct visualization at the target site. FDA 510(k) clearance for the embolization of arteriovenous malformations and hypervascular tumors.

Leadership Team

Mike Mangano - President and CEO ABK Biomedical

Michael Mangano

President and CEO

> an accomplished global executive leader with over 25 years’ experience in the medical device industry. 

Gary - Donofrio - Chief Business Officer ABK Biomedical

Gary Donofrio

Chief Business Officer

> extensive marketing and commercialization experience with over 25 years in the medical device field.

Mike Tyson - CFO ABK Biomedical

Mike Tyson

Chief Financial Officer

> over 35 years’ experience in public accounting and leadership positions.

Mike Tyson - CFO ABK Biomedical

Aravind Arepally, M.D.

Chief Medical Officer

> Chief Medical Officer and practicing Interventional Radiologist with extensive industry and academic experience.

David Dobrowski - VP Clinical Development ABK biomedical

David Dobrowski

Sr. VP of Clinical Development and Regulatory Affairs

> an accomplished Life Sciences Executive and Enterprise Leader with over 25 years of pharmaceutical and medical device development experience. 

Marc Gregoire - VP R&D ABK Biomedical

Mark Gregoire

VP Nuclear Strategy and Development

> an accomplished professional mechanical engineer with extensive experience in the nuclear medical products sector.

Anthony Headley - VP Manufacturing ABK Biomedical

Anthony Headley

Sr. VP, Manufacturing, R&D and Engineering> an accomplished medical device executive with 25 years experience leading and building engineering, manufacturing, and R&D organizations
Lucy Bataneant

Lucy Bataneant, M.D.

Global Head of Medical Affairs> an accomplished medical doctor and researcher with extensive experience in clinical research and medical affairs.

MORE THAN JUST AN EMPLOYER

The ABK Biomedical Team

We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.

ABK Biomedical is an equal opportunity employer offering competitive compensation packages.

ABK's Business Partners

ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.

Research Partners

Development Partners

ABK Biomedical is ISO Certified

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada

T. 902.442.4009

 

Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694
USA

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.

Copyright 2022 - All International Rights Reserved